The JAK-STAT pathway plays a critical role in regulating the immune response, especially cytokines and T cell responses, and is highly associated to IBD pathology, and targeting this pathway using small molecules such as Tofacitinib have shown efficacy in patients with UC but not CD (7, 41). This evidence concerns the gene SOAT1 and inflammatory bowel disease.